These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Human abuse liability evaluation of CNS stimulant drugs. Romach MK; Schoedel KA; Sellers EM Neuropharmacology; 2014 Dec; 87():81-90. PubMed ID: 24793872 [TBL] [Abstract][Full Text] [Related]
23. A Public-Health-Based Vision for the Management and Regulation of Psychedelics. Haden M; Emerson B; Tupper KW J Psychoactive Drugs; 2016; 48(4):243-52. PubMed ID: 27430375 [TBL] [Abstract][Full Text] [Related]
24. Efficacy, tolerability, and safety of serotonergic psychedelics for the management of mood, anxiety, and substance-use disorders: a systematic review of systematic reviews. Dos Santos RG; Bouso JC; Alcázar-Córcoles MÁ; Hallak JEC Expert Rev Clin Pharmacol; 2018 Sep; 11(9):889-902. PubMed ID: 30102078 [TBL] [Abstract][Full Text] [Related]
25. Reviewing the Potential of Psychedelics for the Treatment of PTSD. Krediet E; Bostoen T; Breeksema J; van Schagen A; Passie T; Vermetten E Int J Neuropsychopharmacol; 2020 Jun; 23(6):385-400. PubMed ID: 32170326 [TBL] [Abstract][Full Text] [Related]
26. Serotonergic psychedelics and personality: A systematic review of contemporary research. Bouso JC; Dos Santos RG; Alcázar-Córcoles MÁ; Hallak JEC Neurosci Biobehav Rev; 2018 Apr; 87():118-132. PubMed ID: 29452127 [TBL] [Abstract][Full Text] [Related]
29. Prevalence and epidemiological associates of novel psychedelic use in the United States adult population. Sexton JD; Crawford MS; Sweat NW; Varley A; Green EE; Hendricks PS J Psychopharmacol; 2019 Sep; 33(9):1058-1067. PubMed ID: 30816808 [TBL] [Abstract][Full Text] [Related]
30. Principles of laboratory assessment of drug abuse liability and implications for clinical development. Carter LP; Griffiths RR Drug Alcohol Depend; 2009 Dec; 105 Suppl 1():S14-25. PubMed ID: 19443137 [TBL] [Abstract][Full Text] [Related]
31. Psychedelics and the essential importance of context. Carhart-Harris RL; Roseman L; Haijen E; Erritzoe D; Watts R; Branchi I; Kaelen M J Psychopharmacol; 2018 Jul; 32(7):725-731. PubMed ID: 29446697 [TBL] [Abstract][Full Text] [Related]
32. Treating Addiction: Perspectives from EEG and Imaging Studies on Psychedelics. Tófoli LF; de Araujo DB Int Rev Neurobiol; 2016; 129():157-85. PubMed ID: 27503452 [TBL] [Abstract][Full Text] [Related]
33. Psychedelics as medicines for substance abuse rehabilitation: evaluating treatments with LSD, Peyote, Ibogaine and Ayahuasca. Winkelman M Curr Drug Abuse Rev; 2014; 7(2):101-16. PubMed ID: 25563446 [TBL] [Abstract][Full Text] [Related]
35. Predicting abuse potential of stimulants and other dopaminergic drugs: overview and recommendations. Huskinson SL; Naylor JE; Rowlett JK; Freeman KB Neuropharmacology; 2014 Dec; 87():66-80. PubMed ID: 24662599 [TBL] [Abstract][Full Text] [Related]
36. TCB-2 [(7R)-3-bromo-2, 5-dimethoxy-bicyclo[4.2.0]octa-1,3,5-trien-7-yl]methanamine]: A hallucinogenic drug, a selective 5-HT Di Giovanni G; De Deurwaerdère P Neuropharmacology; 2018 Nov; 142():20-29. PubMed ID: 28987938 [TBL] [Abstract][Full Text] [Related]
37. Psychedelics as an emerging novel intervention in the treatment of substance use disorder: a review. DiVito AJ; Leger RF Mol Biol Rep; 2020 Dec; 47(12):9791-9799. PubMed ID: 33231817 [TBL] [Abstract][Full Text] [Related]
38. Dreams and Psychedelics: Neurophenomenological Comparison and Therapeutic Implications. Kraehenmann R Curr Neuropharmacol; 2017; 15(7):1032-1042. PubMed ID: 28625125 [TBL] [Abstract][Full Text] [Related]
39. Using Psychedelics in Clinical Practice: Comparing Therapeutic Uses and Potential Harms. Tariq R Curr Rev Clin Exp Pharmacol; 2023; 18(2):94-109. PubMed ID: 35319407 [TBL] [Abstract][Full Text] [Related]
40. Guidelines and methodological reviews concerning drug abuse liability assessment. Balster RL; Bigelow GE Drug Alcohol Depend; 2003 Jun; 70(3 Suppl):S13-40. PubMed ID: 12759195 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]